Torrent Pharmaceuticals shares gained nearly 4% in early trade on Monday after the company reported its Q4 FY26 earnings and brokerages highlighted strong growth momentum in the India business along with progress in the JB Pharma integration.
The stock rose as much as 3.84% to ₹4,663.70 on the NSE, touching its 52-week high during the session.
For Q4 FY26, Torrent Pharma reported revenue of ₹4,197 crore, up 41.8% year-on-year from ₹2,959 crore. EBITDA jumped 40.7% YoY to ₹1,356 crore compared to ₹964 crore in the year-ago quarter. However, net profit declined 21.9% to ₹389 crore from ₹498 crore last year, while EBITDA margin slipped marginally to 32.3% from 32.6%.
Morgan Stanley maintained its “Equal-weight” rating with a target price of ₹4,580, stating that the quarter marked the first full reporting period including JB Pharma consolidation. The brokerage noted that excluding JB Pharma, revenue and EBITDA rose 16% YoY, driven by strong India business growth and semaglutide traction.
The brokerage highlighted that Torrent’s India business grew 15%, ahead of IPM growth, while its semaglutide launch captured 38% market share in the generic segment. Torrent expects semaglutide sales of ₹200-250 crore in FY27, making it one of the company’s biggest product launch opportunities.
Jefferies maintained a “Buy” rating with a target price of ₹5,350 and said India growth momentum remained strong at 15% YoY. The brokerage added that the JB Pharma integration is progressing smoothly and the company remains on track to achieve planned cost synergies over the coming years.
At 9:41 AM, Torrent Pharma shares were trading at ₹4,658.30, up 3.84% on the NSE.
Disclaimer:
The article is for informational purposes only and should not be considered as investment advice.